Analyzing SomaLogic (SLGC) & The Competition

SomaLogic (NASDAQ:SLGCGet Rating) is one of 41 publicly-traded companies in the “Commercial physical research” industry, but how does it weigh in compared to its competitors? We will compare SomaLogic to similar businesses based on the strength of its profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Institutional and Insider Ownership

59.3% of SomaLogic shares are owned by institutional investors. Comparatively, 58.4% of shares of all “Commercial physical research” companies are owned by institutional investors. 12.9% of SomaLogic shares are owned by insiders. Comparatively, 11.9% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for SomaLogic and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SomaLogic 0 0 4 0 3.00
SomaLogic Competitors 42 620 1215 24 2.64

SomaLogic presently has a consensus price target of $12.20, indicating a potential upside of 249.57%. As a group, “Commercial physical research” companies have a potential upside of 46.17%. Given SomaLogic’s stronger consensus rating and higher possible upside, research analysts plainly believe SomaLogic is more favorable than its competitors.

Valuation & Earnings

This table compares SomaLogic and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
SomaLogic $81.63 million -$87.55 million -4.20
SomaLogic Competitors $2.80 billion $97.54 million 8.84

SomaLogic’s competitors have higher revenue and earnings than SomaLogic. SomaLogic is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares SomaLogic and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SomaLogic -114.46% -16.76% -14.61%
SomaLogic Competitors -239.39% -12.45% -6.19%

Risk and Volatility

SomaLogic has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, SomaLogic’s competitors have a beta of 5.23, indicating that their average share price is 423% more volatile than the S&P 500.

Summary

SomaLogic competitors beat SomaLogic on 7 of the 13 factors compared.

SomaLogic Company Profile

(Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.